Kim Davis
Something big is arriving at American doorsteps this September, and most of the coverage is burying the lead. Reporters keep writing about the technology. The more pressing question is what happens clinically when a prescription brain stimulation device lands in a patient’s hands at home, with or without a therapist in the loop.
Flow Neuroscience’s FL-100 headset received FDA clearance in December 2025, making it the first at-home transcranial direct current stimulation (tDCS) device authorized to treat moderate-to-severe major depressive disorder in the United States. It goes on sale September 1, 2026, prescription-required, priced between $500 and $800. That’s not cheap, but it’s a fraction of the cost of clinic-based transcranial magnetic stimulation (TMS), which can run $10,000 to $15,000 out of pocket and requires specialized equipment that most ZIP codes simply don’t have. Flow CEO Erin Lee has called the device a “democratization of access,” and that framing isn’t just marketing. It points at a real structural problem in psychiatric care.
The trial data that convinced the FDA is worth sitting with for a moment. A randomized, double-blind study of 174 adults found 58% achieved remission after 10 weeks of use, against a 29% placebo remission rate, according to reporting by Psychiatric Times. Among Flow’s 55,000 European users, where the device has been commercially available for years, 77% reported symptom improvement within three weeks. Those are genuinely strong numbers. They’re also not a guarantee for any individual patient, and that distinction matters enormously for how clinicians and patients should approach this.
- FDA cleared the FL-100 in December 2025; U.S. sales begin September 1, 2026.
- Pivotal trial: 58% remission at 10 weeks vs. 29% for placebo (174 adults).
- Cost is $500–$800, far below clinic-based TMS at roughly $10,000–$15,000.
- FDA authorizes use as standalone treatment or alongside antidepressants and therapy.
- 77% of 55,000 European users reported symptom improvement within three weeks.
What tDCS Actually Does (and Doesn’t Do)
Transcranial direct current stimulation delivers a low-level electrical current through electrodes placed on the scalp, targeting the left dorsolateral prefrontal cortex, a region consistently underactive in major depression. The current doesn’t cause seizures, doesn’t require anesthesia, and doesn’t produce the muscle contractions associated with electroconvulsive therapy. Most users report a mild tingling or warmth during sessions.
What it isn’t: a replacement for addressing the cognitive patterns, relational wounds, or situational stressors that therapy works on directly. The device modulates neuronal excitability. It doesn’t teach distress tolerance. It doesn’t process grief. It doesn’t restructure the thinking habits that keep someone stuck. That’s not a knock on the technology. It’s a description of what any biological treatment does and doesn’t reach.
The FDA authorization specifically allows FL-100 as a standalone treatment or in combination with antidepressants and psychotherapy. That “or” is doing a lot of work. It means clinicians will face real decisions about sequencing, monitoring, and coordination.
How It Compares to Existing Options
Helpful resource: DBT Skills Training Handouts and Worksheets is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)
Patients evaluating the FL-100 against other treatments will be doing the mental math. Here’s a direct comparison of the main depression treatment modalities, including the new device:
| Treatment | Setting | Typical Cost | Requires Prescription | FDA Cleared for Depression |
|---|---|---|---|---|
| Antidepressants (SSRIs/SNRIs) | Home | $10–$50/month (generic) | Yes | Yes |
| Cognitive Behavioral Therapy | Office or telehealth | $100–$300/session | No | N/A (therapy, not a drug/device) |
| Clinic-based TMS | Specialty clinic | $10,000–$15,000 per course | Yes | Yes |
| Ketamine/Esketamine (Spravato) | Certified clinic | $700–$900/session | Yes | Yes |
| FL-100 (tDCS) at home | Home | $500–$800 one-time | Yes | Yes (Dec. 2025) |
The one-time cost model is significant. Unlike Spravato, which requires repeated clinic visits at $700 to $900 each, or antidepressants that accrue monthly, the FL-100 is a device purchase. Flow has insurance negotiations underway, which could reduce the barrier further. If even one major insurer covers it before the end of 2026, adoption will accelerate sharply.
Who Should Actually Use This
The FDA cleared FL-100 for moderate-to-severe major depressive disorder. That’s not mild situational sadness or adjustment disorder. The trial enrolled adults with diagnosed MDD, and the remission rates apply to that population.
The device is likely a strong candidate for patients who can’t access or afford clinic-based TMS, who have tried one or more antidepressants without full remission, who are medically unsuitable for certain medications, or who want to avoid pharmacological treatment entirely. It may also appeal to people in rural or underserved areas where specialty psychiatric care is a two-hour drive.
It’s a worse fit for someone in active crisis, someone whose depression is so severe it’s impairing their ability to use a device consistently, or someone without any clinical oversight at all. The prescription requirement exists for a reason. A prescribing clinician, whether a psychiatrist, primary care physician with psychiatric training, or in some states a psychiatric nurse practitioner, needs to be part of the picture.
What Therapists Need to Know Right Now
If you’re a therapist, your clients will start asking about this before September. Some may arrive having already ordered one. A few things worth knowing:
The device pairs with a companion app that includes guided therapy content. Flow designed it as an adjunct to structured treatment, not a substitute for the therapeutic relationship. Therapists don’t need to become tDCS experts overnight, but they do need a working grasp of what the device does, what side effects to watch for (typically mild, including scalp tingling, headache, or fatigue), and how to communicate with prescribing clinicians when the same patient is in both systems.
The coordination gap is the real clinical risk here. Not the device itself. A patient using FL-100 while also in CBT is potentially getting additive benefit. A patient using it as a reason to drop therapy or delay medication evaluation may be underserved. Telehealth.org’s July 2026 coverage notes that the FDA authorization explicitly contemplates combined use, which places coordination responsibility squarely on the treating team.
That team needs to actually communicate. Calendar a conversation with the prescribing provider before October if you have clients who are candidates. Don’t wait for the patient to broker that connection themselves.
The Access Question Nobody Is Resolving Yet
Flow’s “democratization” framing holds up partly. Five hundred to eight hundred dollars is still out of reach for many people on Medicaid, uninsured patients, or those scraping through a period of unemployment that often accompanies severe depression. Until insurance coverage is confirmed, the FL-100 is genuinely accessible to the middle and upper-middle class, which is a meaningful expansion over clinic-based TMS but not the equity breakthrough the headlines imply.
That said, the device does break one significant barrier: geography. Someone in rural Montana or a small town without a TMS center now has a FDA-cleared neuromodulation option that arrives by mail. That’s real. For the estimated 21 million American adults who experience at least one major depressive episode annually, adding one more evidence-based option to the toolkit, especially one that hits 58% remission in trials, changes the calculus in ways we’re only beginning to map out.
The field will learn a lot from the first wave of U.S. adopters this fall. Pay attention to what emerges. This is a live clinical story, and the evidence base will sharpen considerably over the next 12 to 18 months. For now, the most responsible approach is informed engagement: understand the data, support patients in making decisions with their prescribers, and keep the clinical relationship central to any technology-assisted treatment.
Sources
- First At-Home Depression Device Cleared by FDA (Telehealth.org, July 2026)
- FDA Approves First At-Home Brain Stimulation Device for Depression (Psychiatric Times, July 2026)
- FDA Approves First At-Home Brain Stimulation Device For Depression (Forbes, January 2, 2026)
- FDA Clears Home Brain-Stimulation Device to Help Treat Depression (U.S. News & World Report, December 12, 2025)
Photo: Tima Miroshnichenko via Pexels
This article is for general informational purposes only and does not constitute mental health, medical, or clinical advice. If you are in crisis or experiencing a mental health emergency, please contact the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room. Always consult a licensed mental health professional for care specific to your needs.
Recommended Resources
Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.
- Feeling Good: The New Mood Therapy (~$14), The most clinically studied self-help book for depression, recommended by therapists worldwide as CBT-based self-treatment.
- Depression & Anxiety Therapy Journal (~$10), 8-week guided journal with trigger tracking and mood diary, mirrors the homework your therapist would assign between sessions.
- Depression Therapy Journal (~$10), Daily check-in journal for depression, structured mood tracking and reflection prompts designed around therapeutic principles.
